Figures computed from official regulatory filings — .
Analysttarget 5.36 USD (+20%) · consensus 5/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 20.4% · institutions 72.41% · short 13.9% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Arbutus Biopharma Corp only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
1 buy24 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Roivant Sciences Ltd.track record | Other | $44.8M | SEC |
| Nguyen Tuan | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sawhney Roger | Other | $509.6K | SEC |
| Nguyen Tuan | Exercise | $120.6K | SEC |
| Androski Lindsay | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Androski Lindsay | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nguyen Tuan | Other | $1M | SEC |
| Beardsley Robert A | Exercise | $334.1K | Unusual size | SEC |
| Sawhney Roger | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Androski Lindsay | Exercise | $372.5K | SEC |
| Androski Lindsay | Exercise | $45.9K | SEC |
| Beardsley Robert A | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nguyen Tuan | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Beardsley Robert A | Exercise | $168.1K | Unusual size | SEC |
| Beardsley Robert A | Other | $502.2K | SEC |
| Sawhney Roger | Exercise | $334.1K | SEC |
| Sawhney Roger | Exercise | $175.5K | SEC |
| Nguyen Tuan | Exercise | $927K | SEC |
| Androski Lindsay | Other | $418.4K | SEC |
| Beardsley Robert A | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sawhney Roger | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sawhney Roger | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Beardsley Robert A | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nguyen Tuan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nguyen Tuan | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |